SYFOVRE sales in Q1 are expected to be lower than Q4 due to temporary factors. Medicare Advantage status will gradually impact new patient share. SYFOVRE's competitive advantage lies in its dosing schedule and payer status.
Read MoreDid you find this insightful?
Amazing
Bad
Just Okay